Table D23. Morbidity outcomes 2

| Author, YearTrial Name | Morbidity Outcome 2 | Description of Timing of Measurement of Outcome  | Data source | N | Results |
| --- | --- | --- | --- | --- | --- |
| Bender et al., 20101NA | NA | NA | NA | NA | NA |
| Berg et al., 19972NA | Percent symptom-free days (SD) from a journal of daily asthma concerns on wheeze, coughing, shortness of breath, and chest tightness | Symptoms recorded each day for a week at week 7 | self-report | G1: 31G2: 24 | G1: 44 (38)G2: 60 (37)95% CI NRP<0.1 |
| Bogner et al., 20084NA | Systolic BP, mean (SD), mm Hg - compared at 6 weeks | measured at baseline and at 6 weeks | automated BP monitor | G1: 32G2: 32 | G1: 127.3 (17.7)G2: 141.3 (18.8)95% CI, p: .003 |
| Bogner et al., 20105NA | A1C/Blood glycemic control | 2 times, at BL and 12 weeks | A1C assays | G1: 29G2: 29 | **BL** (%)G1: Mean (SD) = 7.3 (2.3) G2: Mean (SD) = 7.3 (2.0)95% CI, NRp: 0.70**EP** (%)G1: Mean (SD) = 6.7 (2.3)G2: Mean (SD) = 7.9 (2.6)95% CI, NRp: 0.019 |
| Choudhry et al., 201113MI FREEE | rate of total major vascularevents or revascularization | allowing for theoccurrence of more than one event per patient andthe time to the first major vascular event (i.e., theprimary composite outcome excluding revascularization) | health claims data | G1: 2845G2: 3010 | G1: 622 patients; 21.5 per 100 person-yearsG2: 729 patients; 23.3 per 100 person-yearsAdjusted hazard ratio: 0.89, 95% CI, 0.80-0.99p: 0.03 |
| Friedman et al., 199614NA | Diastolic BP | measured at baseline and at 6-months | BP readings by field technicians | G1: 133G2: 134 | G1: 5.4 mm Hg (mean decrease)G2: 3.3 mm Hg (mean decrease)95% CI, NRp: =0.09 |
| Fulmer et al., 199915NA | SF-36 score | Measured at baseline, 10 weeks | self-report | G1: 15G2: 13G3: 14 | Pre-intervention mean (SD) G1: 86.1 (17.0) G2: 81.0 (15.2) G3: 87.3 (24.3) Post-intervention mean (SD) G1: 85.9 (18.9) G2: 90.1 (20.6) G3: 91.7 (22.7)95% CI, NRp: NR"There was no significant change in the SF-36 scores for the sample.… Group membership did not make a difference..." |
| Janson et al., 200320NA | FEV1 (% predicted) at week 7; between group difference in change from baseline to final visit at week 7 (95% CI)  | recorded at every visit | questionnaire | G1: 33G2: 32 | G1: 90 (16)G2: 80 (20)Between group difference: 5 (-1 to 10) p = 0.09 |
| Janson et al., 200921NA | mean change Symptom Score; During intervention(T0-T1), following intervention (T1-T2), and for entire study duration (T0-T2)Symptom-free days (symptom score =0) | "rated daily by participants; scores averaged weekly for analysis"  | rated in subject maintained diaries; 0-10 scale | G1: 45G2: 39 | Mean change:T0-T1G1: -1.28G2: -1.41p: 0.84T1-T2G1: -0.97 G2: 0.1195% CI, p: .06T0-T2G1: -2.25G2: -1.30p: 0.19Symptom-free daysOdds RatiosT0-T1G1: 2.2G2:1.6p: 0.48T1-T2:G1: 2.7G2: 1.8p: .63T0-T2: G1: 5.9G2: 2.8p: 0.51 |
| Katon et al., 199524NA | % patients whose scores on IDS improved ≥50% | 4-month follow-up for bivariate; 1m, 4m and 7m for multivariate and group-by-time interaction | other (specify): clinician-rated | **Major depression group** N=91**Minor depression group** N=126 | **Bivariate:****Major depression group**G1: 61.5G2: 40.695% CI, NR p: <0.08**Minor depression group**G1: 48.0G2: 55.495% CI, NR p: 0.50**Multivariate****Major depression group**G1: NRG2: NR95% CI, NR p: <0.02**Minor depression group**G1: NRG2: NR95% CI, NR p: not significant**Group-by-timeMajor depression group**G1: NRG2: NR95% CI, NR p: NR, but statistically significant |
| Katon et al., 199625NA | 50% or more Improvement on the SCL-20 depression scale | 4-month follow up | SCL-20 scale | G1: 77G2: 76 | Major Depression Group (% showing >50% improvement)G1: 70.4%G2: 42.3%p:0.04NS difference between G1 and G2 in the minor depression groupG1: 66.7%G2: 52.8%p: 0.22  |
| Katon et al., 199926NAKaton et al., 200227NA | Percentage of patients who were asymptomatic (DSM-IV of 0 or 1)(Reported in 9123) | Measured at 3 and 6 months | Structured clinical interview for DSM-IV symptoms | NR | **At 3 mos**.G1: 40% G2: 23%Chi-square: 6.18p: 0.01**At 6 mos**. G1: 44%G2: 31%Chi-square: 3.90p: 0.05 |
| Katon et al., 200128 NALudman et al., 200329NAVan Korff et al., 200330NA | Functional impairment, Disability (Von Korff et al.) | BL, 3, 6, 9, 12 months. | Sheehan Disability Scale, self-report | **BL**G1: 194G2: 192**3 mos**G1: 182G2: 181**6 mos**G1: 172G2: 167**9 mos**G1: 156G2: 145**12 mos**G1: 121G2: 111 | **3 mos** mean (SD)G1: 2.79 (3.94)G2: 2.08 (2.07) 95% CI, NR p: NR**6 mos** mean (SD)G1: 2.41 (3.23)G2: 2.23 (2.22)95% CI, NRp: NR**9 mos** mean (SD)G1: 2.30 (2.06)G2: 2.30 (2.28) 95% CI, NRp: NR**12 mos** mean (SD)G1: 2.09 (1.98)G2: 2.08 (2.07)95% CI, NR p: NREffects:InterventionEstimate: 0.15 (0.17)T-statistic: 0.86p: 0.39TimeEstimate: -0.06 (0.06)T-statistic: 1.06p: 0.29Intervention x timeEstimate: -0.12 (0.08)T-statistic: 1.47p: 0.14 |
| Lin et al., 200632NA | BMI | Measured 2 times, once at baseline and once at endpoint | NR | **BL**G1: 164G2: 165**EP**G1: 164G2: 165 | **BL** (kg/m^2) (Mean (SD))G1: 33.9 (8.6)G2: 36.3 (11.1)95% CI, NRp: <0.05 without adjustment**EP** (kg/m^2)G1: 33.0 (7.9)G2: 36.1 (10.0)95% CI, NRp: <0.01 with adjustment |
| Pearce et al., 200839Cardiovascular Risk Education and Social Support (CaRESS) Trial | Mean systolic BP | 7 times over a 12-month period | Standardized BP readings, following American Heart Association guidelines | **BL** G1 + G2: 108G3: 91**Midpoint:**G1 + G2: 92G3: 74**EP** G1 + G2: 81G3: 60 | **BL**(mmHg)G1 + G2: 141.3G3: 139.095% CI, NRp (G1 + G2 vs. G3): 0.5433 (unadjusted), NR (adjusted)**Midpoint** (mmHg)G1 + G2: 135.5G3: 133.695% CI, NRp (G1 + G2 vs. G3): 0.3836 (unadjusted), 0.4969 (adjusted)**EP**(mmHg)G1 + G2: 134.0G3: 133.895% CI, NRp (G1 + G2 vs. G3): 0.9427 (unadjusted), 0.6475 (adjusted) |
| Rudd et al., 200445NA | Change in diastolic BP between baseline and 6 months | Measured at baseline and at 6 months | Clinic measurement by blinded study personnel | G1: 74G2: 76 | G1: -6.5(95% CI -8.8, -4.1)G2:-3.4(95% CI -5.3, -1.5) p<0.05 |
| Schaffer et al., 200447NA | AQLQmean (SD) | baseline, 3, 6 months; timeframe: specific to time of measurement | questionnaire | G1: 11G2: 10G3:12G4:13 | AQLQ mean (SD)G1Pre: 4.97 (0.88)3 mos: 5.15 (0.91)6 mos: 5.22 (0.99)G2Pre: 4.60 (1.1)3 mos: 4.94 (0.97)6 mos: 5.30 (0.8)G3:Pre: 4.71 (1.16)3 mo: 5.13 (1.32)6 mo: 5.22 (0.98)G4 :Pre: 4.65 (1.23)3 mo: 4.68 (1.49)6 mo: 4.87 (1.2)Pre-3: G4 vs.G2 p = .5 G4 vs. G1 p = .3 G4 vs. G3 p = .6 Pre-6G4 vs. G3 p = .2G4 vs. G2 p = .4G4 vs. G1 p = .8 |
| Schneider et al., 200849NA | Absolute Change in Bp: SBP | 6 and 12 months | Medical chart review | G1: 47G2: 38 | Mean (SD) absolute change**6 mos**G1: -4.2 (21.5)G2: -4.2 (20.9)95% CI, NRp: 0.992**12 mos**G1: -2.7 (16.5)G2: -1.3 (17.8)95% CI, NRp: 0.669 |
| Solomon et al., 199854NAGourley et al., 199855NA | Hypertension group reporting "Feeling dizzy upon standing up, " mean (SD) (Item 8) | Visit 1: BaselineVisit 5: 4-6 months | Hypertension/Lipid Form 5.1 developed by The Health Outcomes Institute; Likert scale of 1 (never) to 5 (very often);  | Overall N: 63G1: NRG2: NR | **Visit 1**G1: 1.7 (1.1)G2: 2.0 (1.1)95% CI, NRp: NR**Visit 5**G1: 1.4 (0.8)G2:1.4 (0.8)95% CI, NRp: NR |
| Wilson et al., 201065Better Outcomes of Asthma Treatment (BOAT) | FEV1:FEV6 ratio | follow-up year 1, measured once | Spirometry | G1: 165G2: 170G2: 172 | G1: 72.8%G3:70.0%p= 0.0005G1: 72.8%G2: 71.8%p: 0.09G2: 71.8%G3: 70.0%p: 0.07 |
| Wolever et al., 201066NA | Hemoglobin A1C (patients with A1C > 7% at baseline) | Twice within a 6-month period | Blood work | G1: 16G2: NR | G1: **BL** mean (SD) = 8.9 (1.78), **EP** mean (SD) = 8.3 (1.76)G2: **BL** mean (SD) = 8.8 (1.95), **EP** mean (SD) = 8.8 (1.99)95% CI, NRp: G1 - Within-group change from baseline = 0.030 |